| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.018 | 0.9 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.023 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.9 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.02 | 0.9 |
| mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |